The meeting of the German Society of Human Genetics (gfh) was held in Weimar, Germany this week and of course the attendees had the opportunity to visit the joined booth of MetaSystems and MetaSystems Probes. Main topics of the exhibition have been the latest advancements of the Neon case and imaging platform and RapidHyb, the revolutionary fast hybridization times of MetaSystems Probes' FISH probes.
XL t(6;9) DEK/NUP214
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl (10 Tests)
Several recurrent balanced translocations and inversions, and their variants, are
recognized in the WHO category AML with recurrent genetic abnormalities. Three new
cytogenetically defined entities were recently incorporated: AML with t(6;9)(p23;q34) DEK/NUP214; AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) RPN1/EVI1 and AML (megakaryoblastic) with t(1;22)(p13;q13) RBM15/MKL1, a rare leukemia most commonly
occurring in infants.
The t(6;9)(p23;q34) DEK/NUP214 fusion occurs with an incidence of 1–5% in adult patients with AML. This translocation tends to occur in younger adults and is associated with an unfavorable prognosis at diagnosis. Although the t(6;9) is usually the sole cytogenetic aberration at diagnosis, additional karyotypic abnormalities are frequently identified during disease progression.
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO).
- Shearer et al (2005) Leukemia 19: 126-131
- Doehner et al (2010) Blood 115: 453-474
- Sandahl et al (2014) Haematologica 99: 865-872